November 2014 Newsletter

Survey Presentation at Spanish Ministry of Health On November 25, Executive Director Michael Reilly presented the European Survey results at the “1st EuropaBio – ASEBIO Meeting on Innovation and Biological Therapies” at the Spanish Ministry of Health, Social Services and Equality in Madrid. The event was hosted by EuropaBio and the Spanish Bioindustry Association (ASEBIO) and […]

Read More


October 2014 Newsletter

ASBM Presents to WHO in Geneva On October 15, ASBM Chairman Dr. Gewanter and Executive Director Michael Reilly traveled to Geneva, Switzerland to participate in the World Health Organization’s (WHO) 59th International Nonproprietary Naming Stakeholders Session.  The Geneva meeting was Dr. Gewanter’s first public appearance as ASBM Chairman, a role he assumed on September 1 […]

Read More


September 2014 Newsletter

ASBM and Patient Groups Support WHO BQ Proposal   In July, the World Health Organization’s (WHO) Programme on International Nonproprietary Names (INN) released their draft Biological Qualifier (BQ) proposal that would assign a four-letter alphabetic code at random to a biological active substance manufactured at a specific site. The WHO proposal outlined a plan for […]

Read More


Summer 2014 Newsletter

ASBM Announces New Chairman and IAB Chair The Alliance for Safe Biologic Medicines (ASBM) recently announced pediatric rheumatologist and current ASBM International Advisory Board (IAB) member, Harry L. Gewanter, MD, FAAP, FACR as ASBM’s incoming chairman. Dr. Gewanter succeeds outgoing chairman Richard Dolinar, MD, who served as ASBM’s initial chairman since 2011. In addition, Philip […]

Read More


June 2014 Newsletter

ASBM Shares EU Physician Survey in Paris Michael Reilly, Executive Director of the Alliance for Safe Biologic Medicines, (ASBM) was featured as an expert panelist at the “Understanding Biologic Medicine: Science, Regulatory Policy and the Changing Dynamics of Biosimilars” event hosted by AbbVie on June 10th in Paris, France. The two-part event was webcast worldwide […]

Read More


May 2014 Newsletter

GaBI Publishes ASBM Whitepaper on European Prescriber Survey On June 5, The Generics and Biosimilars Initiative Journal published a paper authored by ASBM’s Chairman Richard Dolinar, MD and its Executive Director Michael Reilly. The paper is based on data collected by ASBM for its 2013 survey of 470 prescribing physicians with clinical experience using biologics […]

Read More


April 2014 Newsletter

Lawmaker Presses FDA for Guidance on Naming, Interchangeability Policies In a letter to FDA Commissioner Margaret Hamburg dated April 24, U.S. Rep. Anna Eshoo (D-CA) requested an update on FDA’s timeline for releasing guidance on biosimilar naming and interchangeability. “I believe clear and timely guidance on naming and interchangeability will allow both innovators and manufacturers […]

Read More


March 2014 Newsletter

ASBM Releases EU Physicians’ Survey in Brussels On March 18th in Brussels, the Alliance for Safe Biologic Medicines (ASBM) released the results of a survey of 470 European physicians from five countries regarding their prescribing habits and knowledge of biosimilar medicines. Participants in the survey included specialists in the fields of nephrology, rheumatology, dermatology, neurology, […]

Read More


February 2014 Newsletter

ASBM Forum Brings Together Leaders on Biosimilars Issues in 2014 On February 25th, the Alliance for Safe Biologic Medicines (ASBM) held a forum to educate patient advocates, physician groups and members of its International Advisory Board on the complex issues related to biosimilars. The half-day forum entitled, “Ensuring Access to Safe Biosimilars: Policy Developments and […]

Read More


January 2014 Newsletter

WHO’s Minutes Reflect INN Consideration of Separate Process for ‘Biologic Qualifiers’ for Biosimilars As reported in Inside Health Policy’s “WHO Mulls ‘Biological Qualifier,’ Separate from INN, For Biosimilars,” minutes from the meeting held this past October in Geneva reflect the serious examination by World Health Organization to create a system for unique names. ASBM chairman […]

Read More